logo

For the Inventor, By the Inventor

Seattle, WA, United States of America

Henrik Clausen

This inventor holds 9 USPTO granted patents. Top assignees: The Biomembrane Institute, Jichi Medical School. Active years: 1989-1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Henrik Clausen. Retrieved from https://idiyas.com/inventor/henrik-clausen-53x5az6f

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 9

% Patents Active = 100.0

Average Co-Inventor Count = 2.7

ph-index = 6

Forward Citations = 115(Granted Patents)


Location History:

  • King County, WA (US) (1991)
  • Seattle, WA (US) (1989 - 1998)

Company Filing History:

goldMedal9 out of 37 
 
The Biomembrane Institute
 patents
silverMedal1 out of 1 
 
Jichi Medical School
 patent
where one patent can have more than one assignee

Years Active: 1989-1998

Loading Chart...
9 patents (USPTO):Explore Patents
1. 5747048 - Monoclonal antibodies and vaccine development directed to human (1998-05-05),
2. 5660834 - Monoclonal antibodies and vaccine development directed to human (1997-08-26),
3. 5421733 - Synthesis of Le.sup.x ; dimeric Le.sup.x (difucosyl Y.sub.2 ; III.sup.3 (1995-06-06),
4. 5418129 - Blood treatment method (1995-05-23),
5. 5240833 - Method for the production of monoclonal antibodies directed to (1993-08-31),
6. 5229289 - Monoclonal antibodies and vaccine development directed to human (1993-07-20),
7. 5068191 - Purified histo-blood group A glycosyltransferase and antibodies thereto (1991-11-26),
8. 4942224 - A-associated H-antigens, monoclonal antibodies specific thereto and (1990-07-17),
9. 4857639 - A-associated H-antigens, monoclonal antibodies specific thereto and (1989-08-15),

Title: The Innovative Contributions of Henrik Clausen

Introduction

Henrik Clausen is a prominent inventor based in Seattle, WA, known for his significant contributions to the field of biomedical research. With a total of 9 patents to his name, Clausen has focused on developing monoclonal antibodies and vaccines aimed at combating cancer. His work has the potential to revolutionize cancer treatment and prevention.

Latest Patents

Clausen's latest patents include groundbreaking methods for producing monoclonal antibodies that target human cancer-associated mucin-type glycoprotein antigens. His innovative approach involves immunizing a host with a core structure of a mucin-type glycoprotein, followed by a series of steps to create hybridoma cells that produce the desired antibodies. Additionally, he has developed a vaccine designed to prevent the growth and replication of cancer cells expressing mucin-type glycoproteins. This vaccine comprises a purified mucin-type glycoprotein or a chemically synthesized carbohydrate determinant, which is conjugated to a carrier peptide or macromolecule. The methods he has devised for passive and active immunization further enhance the potential of his discoveries.

Career Highlights

Throughout his career, Clausen has worked with notable institutions such as the Biomembrane Institute and Jichi Medical School. His research has not only advanced the understanding of cancer biology but has also paved the way for new therapeutic strategies. His dedication to innovation in the medical field has made him a respected figure among his peers.

Collaborations

Clausen has collaborated with esteemed colleagues, including Anil Singhal and Sen-Itiroh Hakomori. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their research.

Conclusion

Henrik Clausen's contributions to the field of cancer research through his innovative patents and collaborative efforts highlight his commitment to improving patient outcomes. His work continues to inspire future advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…